1. Home
  2. RYTM vs REZI Comparison

RYTM vs REZI Comparison

Compare RYTM & REZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$105.64

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Resideo Technologies Inc.

REZI

Resideo Technologies Inc.

HOLD

Current Price

$36.22

Market Cap

4.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
REZI
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Wholesale Distributors
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
4.7B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
RYTM
REZI
Price
$105.64
$36.22
Analyst Decision
Strong Buy
Buy
Analyst Count
14
3
Target Price
$131.14
$39.67
AVG Volume (30 Days)
872.9K
1.4M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
N/A
EPS
N/A
0.17
Revenue
N/A
$7,472,000,000.00
Revenue This Year
$55.34
$6.81
Revenue Next Year
$86.06
$3.62
P/E Ratio
N/A
$218.03
Revenue Growth
N/A
10.52
52 Week Low
$74.50
$23.91
52 Week High
$122.20
$45.29

Technical Indicators

Market Signals
Indicator
RYTM
REZI
Relative Strength Index (RSI) 53.92 61.17
Support Level $98.30 $33.18
Resistance Level $113.51 $36.51
Average True Range (ATR) 4.38 1.89
MACD -1.22 0.63
Stochastic Oscillator 21.67 76.64

Price Performance

Historical Comparison
RYTM
REZI

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About REZI Resideo Technologies Inc.

Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.

Share on Social Networks: